Robert Bradway

Chief Executive and Chairman

Amgen Inc.

THE LATEST: In January, Amgen strengthened its presence in China — the world's second-largest pharmaceutical market — by establishing a strategic partnership with Beijing-based biotechnology company BeiGene, focused on development of cancer therapies. Bradway has said he expects 25% of the company&s growth to come from Asian markets during the next decade. In October, Bradway told securities analysts Amgen will focus on developing drugs to treat cancer, cardiovascular disease and inflammatory disease. The company plans to phase out development of drugs to treat neurological diseases and conditions.

BACKGROUND: Bradway joined Amgen in 2006, becoming chief executive in 2012 and board chairman a year later. Prior to Amgen, he worked as managing director at Morgan Stanley in London. He is a member of USC's board of trustees and the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at USC. He's on the board at the Pharmaceutical Research and Manufacturers of America and chairman of the CEO Roundtable on Cancer, a nonprofit devoted to cancer treatment and prevention.

YEARS ON THE LA500: 5

Return to the 2020 edition of the LA500.

Reader Poll

READER POLL: Has the Covid-19 pandemic affected your company’s plans to move or expand your office space?

Reader Poll

READER POLL: Has the Covid-19 pandemic affected your company’s plans to move or expand your office space?